Key Drivers
- Strong liquidity
- No revenue
- Persistent losses
AIAI Summary
REPL has shifted from a generic high-burn biotech to a near-term FDA catalyst play, with enough cash to wait for the August 2, 2026 RP1 decision but still facing a binary outcome where approval could drive a rerating and any delay or rejection would likely trigger dilution and downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •No revenue
- •Persistent losses
REPL has a very strong, cash-rich balance sheet with low debt, but no revenue, persistent losses, and weak efficiency make profitability the main concern.
Price Behavior
Key Price Behavior Insights:
- •Support Rebound
- •Clear Resistance
- •Momentum Fade
REPL is technically fragile after repeated failures at $11.50-$11.60, though the rebound from $9.52 to $10.23 suggests short-term support and a possible base if resistance is reclaimed.
Sharp drop from $11.58 to $9.52 showed fading momentum and higher volatility
Sentiment & News
Key News Insights:
- •FDA resubmission
- •Melanoma data
- •Governance probe
REPL is at a pivotal FDA stage for RP1 in advanced melanoma, but recent momentum and clinical progress are now tempered by a governance investigation.
The stock may remain volatile as investors balance a near-term regulatory catalyst against added legal and board-risk overhang
Similar Companies in Healthcare
Other companies in the same sector with AI ratings